Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Structure Therapeutics Inc.NASDAQ: GPCR
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $18.57M rose 18.0% year over year, behind the +31.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 18.8% from the prior quarter. Over 3 fiscal years it compounded at +55.5% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +24.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $18.57M-18.8% QoQ
- Last fiscal yearDec 2025
- $61.55M+24.6% YoY
- LTMJun 2026
- $73.81M+31.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +18.0% | -100.0% | -118.0 pp |
| 1 year | +24.6% | -100.0% | -124.6 pp |
| 3-year CAGR | +55.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 61.55M USD
- Year-over-year change
- +24.6%
- 4-year CAGR
- +63.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.55M | +24.6% |
| FY2024 | 2024-12-31 | 49.41M | +51.2% |
| FY2023 | 2023-12-31 | 32.67M | +99.6% |
| FY2022 | 2022-12-31 | 16.37M | +90.7% |
| FY2021 | 2021-12-31 | 8.59M | — |
Selling, General & Admin vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 selling, general & admin of $73.81M is the highest of the 8 companies compared; the peer median is $36.57M.
- Its year-over-year change of +31.8% is the 4th highest of 7, against a peer median of +32.9%.
- Over three fiscal years its annual growth of +55.5% compares with a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $73.81M | +31.8% | +55.5% | — | |
| LTM Jun 2026 | $69.2M | +144.0% | +94.7% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $49.23M | — | — | — |
| LTM Mar 2026 | $39.04M | +38.9% | +14.7% | 195.2% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M | +38.0% | — | 38.0% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $16.17M | -36.6% | -2.6% | — | |
| LTM Mar 2026 | $15.87M | +18.9% | +7.0% | 43.1% | |
| Peer median (excluding GPCR) | $36.57M | +32.9% | +14.7% | 119.1% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.9M |
| Gross Profit | 0 | 0 | 0 | 0 | (3.9M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.11M | 36.19M | 70.1M | 108.81M | 225.26M |
| Selling, General & Admin | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M |
| Operating Expenses | 37.7M | 52.56M | 102.78M | 158.23M | 283.67M |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 3.9M |
| EBITDA | (37.62M) | (51.03M) | (75.7M) | (121.22M) | (136.79M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.7M) | (52.56M) | (102.78M) | (158.23M) | (287.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 122 | 1.26M | 13.38M | 36.03M | 35.97M |
| Interest Expense | 122.16K | 0 | 13.39M | 0 | 0 |
| Other Income / Expenses | (122K) | 1.26M | 13.39M | 36.01M | 146.51M |
| Income Before Tax | (37.82M) | (51.3M) | (89.38M) | (122.22M) | (140.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 231K | 17K | 236K | 310K | 515K |
| Net Income | (40.01M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| EPS (Diluted) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| Weighted Avg Shares | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
| Weighted Avg Shares (Diluted) | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.